ENTITY

Shield Therapeutics (STX LN)

40
Analysis
Health CareUnited Kingdom
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease. Its products pipeline includes PT20, a novel iron-based phosphate binder for the treatment of hyperphosphatemia related to chronic kidney disease (CKD); PT30 and PT40 that are intravenous iron formulations; and Feraccru to treat patients with IDA related to CKD and other indications. The company was founded in 2008 and is based in Gateshead Quays, the United Kingdom.
more
Company Event23 Apr 2026 14:00 • Upcoming
Add To Calendar
Company Event23 Oct 2025 22:00 • Latest
Company Event03 Sep 2025 14:00 • Upcoming
Add To Calendar
Company Event23 Jul 2025 22:00
Company Event24 Apr 2025 14:00 • Upcoming
Add To Calendar
x